Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 869, Issue 1-2, 2008, Pages 31-37

  Binkhathlan, Ziyad ^a   Somayaji, Vishwa ^a   Brocks, Dion R ^a   Lavasanifar, Afsaneh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

LC MS; Pharmacokinetics; PSC 833; Valspodar

Indexed keywords

ACETONITRILE; BIOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHARMACOKINETICS;

AMMONIUM HYDROXIDE; PSC 833; VALSPODAR;

RATS;

ACETONITRILE; AMIODARONE; AMMONIUM HYDROXIDE; VALSPODAR;

ANALYTIC METHOD; ANALYTICAL ERROR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; ELUTION; ION MONITORING; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETER; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; VALIDATION PROCESS;

AMIODARONE; ANIMALS; CALIBRATION; CHROMATOGRAPHY, LIQUID; CYCLOSPORINS; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

RATTUS;

EID: 44749093654     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.05.003     Document Type: Article

References (42)

1. Ford J.M., and Hait W.N. Pharmacol. Rev. 42 (1990) 155
2. Chin K.V., Pastan I., and Gottesman M.M. Adv. Cancer Res. 60 (1993) 157
3. Aouali N., Eddabra L., Macadre J., and Morjani H. Crit. Rev. Oncol. Hematol. 56 (2005) 61
4. Krishna R., and Mayer L.D. Eur. J. Pharm. Sci. 11 (2000) 265
5. Sikic B.I. Oncology (Williston Park) 13 (1999) 183
6. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., and Chen G. Cancer Chemother. Pharmacol. 40 Suppl. (1997) S13
7. Juliano R.L., and Ling V. Biochim. Biophys. Acta 455 (1976) 152
8. Hirose M. Int. J. Hematol. 76 Suppl. 2 (2002) 206
9. Israeli D., Ziaei S., Gonin P., and Garcia L. J. Theor. Biol. 232 (2005) 41
10. Kartner N., Riordan J.R., and Ling V. Science 221 (1983) 1285
11. Sparreboom A., and Nooter K. Drug Resist. Updat. 3 (2000) 357
12. Kuppens I.E., Breedveld P., Beijnen J.H., and Schellens J.H. Cancer Invest. 23 (2005) 443
13. Boesch D., Muller K., Pourtier-Manzanedo A., and Loor F. Exp. Cell Res. 196 (1991) 26
14. Lemaire M., Bruelisauer A., Guntz P., and Sato H. Cancer Chemother. Pharmacol. 38 (1996) 481
15. Kusunoki N., Takara K., Tanigawara Y., Yamauchi A., Ueda K., Komada F., Ku Y., Kuroda Y., Saitoh Y., and Okumura K. Jpn. J. Cancer Res. 89 (1998) 1220
16. Watanabe T., Tsuge H., Oh-Hara T., Naito M., and Tsuruo T. Acta Oncol. 34 (1995) 235
17. Gottesman M.M., and Pastan I. Annu. Rev. Biochem. 62 (1993) 385
18. Boesch D., Gaverieaux C., Jachez B., and Loor F. Cancer Res. 51 (1991) 4226
19. Cagliero E., Ferracini R., Morello E., Scotlandi K., Manara M.C., Buracco P., Comandone A., Baroetto Parisi R., and Baldini N. Oncol. Rep. 12 (2004) 1023
20. Keller R.P., Altermatt H.J., Donatsch P., Zihlmann H., Laissue J.A., and Hiestand P.C. Int. J. Cancer 51 (1992) 433
21. Sonneveld P., Schoester M., and de Leeuw K. J. Clin. Oncol. 12 (1994) 1584
22. Boote D.J., Dennis I.F., Twentyman P.R., Osborne R.J., Laburte C., Hensel S., Smyth J.F., Brampton M.H., and Bleehen N.M. J. Clin. Oncol. 14 (1996) 610
23. Lum B.L., Kaubisch S., Yahanda A.M., Adler K.M., Jew L., Ehsan M.N., Brophy N.A., Halsey J., Gosland M.P., and Sikic B.I. J. Clin. Oncol. 10 (1992) 1635
24. Chico I., Kang M.H., Bergan R., Abraham J., Bakke S., Meadows B., Rutt A., Robey R., Choyke P., Merino M., Goldspiel B., Smith T., Steinberg S., Figg W.D., Fojo T., and Bates S. J. Clin. Oncol. 19 (2001) 832
25. Bates S.E., Bakke S., Kang M., Robey R.W., Zhai S., Thambi P., Chen C.C., Patil S., Smith T., Steinberg S.M., Merino M., Goldspiel B., Meadows B., Stein W.D., Choyke P., Balis F., Figg W.D., and Fojo T. Clin. Cancer Res. 10 (2004) 4724
26. Giaccone G., Linn S.C., Welink J., Catimel G., Stieltjes H., van der Vijgh W.J., Eeltink C., Vermorken J.B., and Pinedo H.M. Clin. Cancer Res. 3 (1997) 2005
27. Kivisto K.T., Kroemer H.K., and Eichelbaum M. Br. J. Clin. Pharmacol. 40 (1995) 523
28. Fischer V., Rodriguez-Gascon A., Heitz F., Tynes R., Hauck C., Cohen D., and Vickers A.E. Drug Metab. Dispos. 26 (1998) 802
29. Kovarik J.M., Mueller E.A., Richard F., and Tetzloff W. J. Clin. Pharmacol. 37 (1997) 1009
30. Kornblau S.M., Estey E., Madden T., Tran H.T., Zhao S., Consoli U., Snell V., Sanchez-Williams G., Kantarjian H., Keating M., Newman R.A., and Andreeff M. J. Clin. Oncol. 15 (1997) 1796
31. Bates S., Kang M., Meadows B., Bakke S., Choyke P., Merino M., Goldspiel B., Chico I., Smith T., Chen C., Robey R., Bergan R., Figg W.D., and Fojo T. Cancer 92 (2001) 1577
32. Fracasso P.M., Westervelt P., Fears C.L., Rosen D.M., Zuhowski E.G., Cazenave L.A., Litchman M., and Egorin M.J. J. Clin. Oncol. 18 (2000) 1124
33. Scott M.G., Hock K.G., Crimmins D.L., and Fracasso P.M. Clin. Chem. 43 (1997) 505
34. Lush R.M., Meadows B., Fojo A.T., Kalafsky G., Smith H.T., Bates S., and Figg W.D. J. Clin. Pharmacol. 37 (1997) 123
35. van Tellingen O., Kemper M., Tijssen F., van Asperen J., Nooijen W.J., and Beijnen J.H. J. Chromatogr. B, Biomed. Sci. Appl. 719 (1998) 251
36. Mueller E.A., Kovarik J.M., Uresin Y., Preisig-Fluckiger S.S., Hensel S., Lucker P.W., and Holt B. J. Clin. Pharmacol. 37 (1997) 1001
37. Yatscoff R.W., Copeland K.R., and Faraci C.J. Clin. Chem. 36 (1990) 1969
38. Watanabe T., Nakayama Y., Naito M., Oh-hara T., Itoh Y., and Tsuruo T. Anticancer Drugs 7 (1996) 825
39. Chimalakonda A.P., Shah R.B., and Mehvar R. J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci. 772 (2002) 107
40. Brocks D.R. Biopharm Drug Dispos. 21 (2000) 365
41. FDA, U.S. Department of Health and Human Services, Rockville, 2001.
42. Brocks D.R., Ala S., and Aliabadi H.M. Biopharm Drug Dispos. 27 (2006) 7